चिन्ह | एक्सचेंज | करेंसी |
|---|
Oncopeptides AB (publ), a biotech company, engages in the commercialization, and research and development of treatments for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is melflufen, a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden
| औसत | 21.333 (+157.773% ऊपर) |
| उच्च | 35.000 |
| निम्न | 14.000 |
| क़ीमत | 8.276 |
| विश्लेषकों की संख्या | 3 |
प्रकार | 5 मिनट | 15 मिनट | प्रति घंटा | दैनिक | मासिक |
|---|---|---|---|---|---|
| मूविंग एवरेज | खरीदें | बेचना | बेचना | मजबूत विक्रय | मजबूत विक्रय |
| तकनीकी संकेतक | मजबूत खरीद | बेचना | मजबूत विक्रय | बेचना | मजबूत विक्रय |
| सारांश | मजबूत खरीद | बेचना | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय |
नाम | अंतिम | उच्च | निम्न | बदलाव | बदलाव % | वॉल्यूम | समय | ||
|---|---|---|---|---|---|---|---|---|---|
| 13.19 | 13.29 | 12.03 | +0.53 | +4.19% | 190.66K | BSE | |||
| 3,340.15 | 3,368.50 | 3,309.95 | +15.75 | +0.47% | 140.25K | NSE | |||
| 380.00 | 382.40 | 375.05 | +4.60 | +1.23% | 152.27K | NSE | |||
| 2,104.00 | 2,177.80 | 2,078.00 | -56.65 | -2.62% | 480.31K | NSE | |||
| 0.80 | 0.80 | 0.80 | 0.00 | 0.00% | 0.00 | NSE | |||
| 2,025.00 | 2,073.55 | 2,020.00 | -0.55 | -0.03% | 136.96K | NSE | |||
| 0.64 | 0.64 | 0.61 | 0.00 | 0.00% | 715.88K | BSE | |||
| 1,435.00 | 1,460.00 | 1,417.15 | -36.90 | -2.51% | 72.10K | NSE | |||
| 2,324.85 | 2,327.00 | 2,292.95 | +19.15 | +0.83% | 625.23K | NSE | |||
| 106.05 | 109.25 | 106.00 | -2.20 | -2.03% | 52.91K | NSE | |||
| 377.00 | 398.00 | 373.95 | -17.40 | -4.41% | 266.46K | NSE | |||
| 3.88 | 3.88 | 3.88 | +0.18 | +4.86% | 5.00 | BSE | |||
| 0.90 | 0.94 | 0.90 | 0.00 | 0.00% | 0.00 | BSE | |||
| 845.00 | 879.40 | 836.60 | -14.40 | -1.68% | 393.31K | NSE | |||
| 913.50 | 913.50 | 840.00 | +152.25 | +20.00% | 21.05K | BSE |